Overview

Retinal Sensitivity in BRVO After Anti-VEGF Therapy

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:
0

Participant gender:
All

Summary

The efficacy of anti-vascular endothelial growth factor (VEGF) therapy for branch retinal vein occlusion (BRVO) is shown, but its effect on retinal sensitivity is not fully investigated. The purpose of this study is to compare the changes in retinal sensitivity after ranibizumab therapy or combination therapy of ranibizumab and laser photocoagulation in eyes with BRVO.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Fukushima Medical University

Treatments:

Bevacizumab
Ranibizumab

Criteria

Inclusion Criteria:

- Treatment naive patients of branch retinal vein occlusion with visual acuity of less
than 1.0 and macular edema of more than 250 micrometers in foveal thickness.

Exclusion Criteria:

- Patients with history of treatment for branch retinal vein occlusion, possibility of
pregnancy, allergy for ranibizumab, intraocular infection, or severe inflammation will
be excluded.